# Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin

> **NCT00230854** · PHASE1 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 28 (—)

## Conditions studied

- Chronic Hepatitis C
- Hepatitis, Viral, Human

## Interventions

- **DRUG:** EMZ702

## Key facts

- **NCT ID:** NCT00230854
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 28 (—)
- **Last updated:** 2019-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230854, "Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00230854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*